[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499053":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":40,"collaborators":44,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Second Xiangya Hospital of Central South University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy",null,[12],"Diagnostic Test: WES and ctDNA detection",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST","WES and ctDNA detection",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Yan Hu, M.D., Ph.D.","CONTACT","8685296122","yanhu@csu.edu.cn",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China","RECRUITING","Changsha","Hunan","410011","China",{"type":33,"coordinates":34},"Point",[35,36],112.97087,28.19874,{"lat":36,"lon":35},[39],{"name":20,"role":21,"phone":10,"phoneExt":10,"email":23},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Liu Wenliang","Professor",[45],{"name":46,"class":47},"Shanghai OrigiMed Co., Ltd.","UNKNOWN","100499053",false,"NCT05778253","The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC","Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)","Inclusion Criteria:\n\n* Histopathology or cytology confirmed the lung squamous cell carcinoma\n* Age ranging from 18 to 75\n* Agree to participate in this study and sign an informed consent form\n* Treatment-naive tumor\n* According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor\n* Sufficient tissue\u002Fblood samples are available to meet research requirements\n* The ECOG PS score is 0-1\n\nExclusion Criteria:\n\n* Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form\n* Non-squamous NSCLC\n* Unresectable IIIa-IIIb tumor\n* Patients with solid organ or blood system transplantation\n* Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors\n* Patients with interstitial lung disease\n* Patients with acute or chronic infectious disease\n* Pregnant and lactating women\n* Patients who have undergone other clinical drug trials","ALL","18 Years","75 Years",{"count":58,"type":59},50,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.",[63],"Lung Squamous Cell Carcinoma","2023-03-18",{"date":66,"type":67},"2023-03-21","ACTUAL",{"date":69,"type":59},"2023-03-23",{"date":71,"type":59},"2029-09-23",{"name":5,"class":6},1]